Trial Profile
A Phase 2 Randomized Open-Label Study of Oral Darolutamide (ODM-201) vs. Androgen Deprivation Therapy (ADT) With LHRH Agonists or Antagonist in Men With Hormone Naive Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Darolutamide (Primary) ; Degarelix; Goserelin; Leuprorelin; Triptorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- 04 Apr 2024 Planned End Date changed from 1 May 2024 to 1 Dec 2036.
- 22 Mar 2024 This trial has been completed in Austria, according to European Clinical Trials Database record.
- 06 Sep 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.